Antiplatelet therapy is known to decrease the risk of secondary ischemic stroke. However, the effectiveness and safety of antiplatelet therapy in patients with end-stage renal disease are uncertain, especially in dialysis.
Aims and/or hypothesis
We estimated the effectiveness and safety of antiplatelet drugs (aspirin and clopidogrel) for the prevention of recurrent ischemic stroke in end-stage renal disease patients undergoing dialysis during long-term follow-up after first-time ischemic stroke.
Methods
The cases were identified from the National Health Insurance Research Database. Antiplatelet therapy was administered for 11 years to patients experiencing a first ischemic stroke between 1998 and 2006. Primary outcomes, including death and readmission to hospital for stroke, and secondary outcomes, including death, stroke, and acute myocardial infarction or bleeding, were examined.
Results
In total, 1936 patients experienced a first ischemic stroke during the follow-up. In a time-dependent analysis, the hazard ratio for primary outcomes in patients treated with aspirin was 0·671 (P < 0·001) and that for clopidogrel was 0·933 (P = 0·497). At secondary outcomes, patients treated with aspirin, hazard ratio for readmission for stroke was 0·715 (P = 0·002) and that for bleeding was 0·885 (P = 0·291). Independent risk factors for mortality and readmission due to ischemic stroke included age, diabetes mellitus, and administration of proton pump inhibitors.
Conclusions
Antiplatelet therapy, especially aspirin, still offers safe and effective treatment for ischemic stroke prevention in patients with end-stage renal disease undergoing dialysis.
BauerCMelamedMLHostetterTH. Staging of chronic kidney disease: Time for a course correction. J Am Soc Nephrol2008; 19: 844–6.
2.
GilmoreJ. KDOQI clinical practice guidelines and clinical practice recommendations – 2006 updates. Nephrol Nurs J2006; 33: 487–8.
3.
RiosDRCarvalhoMLwaleedBASimoes e SilvaACBorgesKBDusseLM. Hemostatic changes in patients with end stage renal disease undergoing hemodialysis. Clin Chim Acta2010; 411: 135–9.
4.
MezzanoDTagleRPanesO. Hemostatic disorder of uremia: The platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost1996; 76: 312–21.
5.
NaralaKRHassanSLalondeTAMcCulloughPA. Management of coronary atherosclerosis and acute coronary syndromes in patients with chronic kidney disease. Curr Probl Cardiol2013; 38: 165–206.
6.
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis2002; 39: S1–266.
7.
OcakGVerduijnMVossenCY. Chronic kidney disease stages 1–3 increase the risk of venous thrombosis. J Thromb Haemost2010; 8: 2428–35.
8.
Olechnowicz-TietzSGlubaAParadowskaABanachMRyszJ. The risk of atherosclerosis in patients with chronic kidney disease. Int Urol Nephrol2013; 45: 1605–12.
9.
StefanadisCI. Complex interrelationships between heart and kidneys: Establishing the role of cardiorenal syndrome. Hellenic J Cardiol2010; 51: 87–8.
10.
KahnMRRobbinsMJKimMCFusterV. Management of cardiovascular disease in patients with kidney disease. Nat Rev Cardiol2013; 10: 261–73.
11.
CasserlyLFDemberLM. Thrombosis in end-stage renal disease. Semin Dial2003; 16: 245–56.
BasraSSTsaiPLakkisNM. Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease. J Am Coll Cardiol2011; 58: 2263–9.
15.
CastilloRLozanoTEscolarGRevertLLopezJOrdinasA. Defective platelet adhesion on vessel subendothelium in uremic patients. Blood1986; 68: 337–42.
16.
FurieKLKasnerSEAdamsRJ. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke2011; 42: 227–76.
17.
AndersonJLAdamsCDAntmanEM. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol2007; 50: e1–157.
18.
EastonJD. Clinical aspects of the use of clopidogrel, a new antiplatelet agent. Semin Thromb Hemost1999; 25: 77–82.
19.
GugliucciAKotaniKKinugasaEHermoRCaccavelloRKimuraS. Serum aspirin esterase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after haemodialysis. Ann Clin Biochem2010; 47: 559–63.
20.
ClissoldSP. Aspirin and related derivatives of salicylic acid. Drugs1986; 32: 8–26.
21.
GearaASAzziNBassilCEl-SayeghS. Aspirin resistance in hemodialysis patients. Int Urol Nephrol2012; 44: 323–5.
22.
KaufmanJSFioreLHasbargenJAO'ConnorTZPerdrisetG. A pharmacodynamic study of clopidogrel in chronic hemodialysis patients. J Thromb Thrombolysis2000; 10: 127–31.
23.
TanrikuluAMOzbenBKocMPapila-TopalNOzbenTCaymazO. Aspirin resistance in patients with chronic renal failure. J Nephrol2011; 24: 636–46.
24.
HtunPFateh-MoghadamSBischofsC. Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. J Am Soc Nephrol2011; 22: 627–33.
25.
DengJHanYLWangXZZhaoXZhangHZhouTN. Effects of chronic kidney disease on platelet response to antiplatelet therapy in acute myocardial infarction patients. Zhonghua Yi Xue Za Zhi2012; 92: 2674–6.
26.
AlexopoulosDXanthopoulouIPlakomytiTEGoudasPKoutrouliaEGoumenosD. Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis. Am J Kidney Dis2012; 60: 332–3.
27.
BestPJSteinhublSRBergerPB. The efficacy and safety of short-and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J2008; 155: 687–93.
28.
ChenCYLeeKTLeeCTLaiWTHuangYB. Effectiveness and safety of antiplatelet therapy in stroke recurrence prevention in patients with liver cirrhosis: A 2-year follow-up study. Pharmacoepidemiol Drug Saf2012; 21: 1334–43.
29.
GislasonGHRasmussenJNAbildstrømSZ. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J2006; 27: 1153–8.
30.
BushnellCDOlsonDMZhaoX. Secondary preventive medication persistence and adherence 1 year after stroke. Neurology2011; 77: 1182–90.
31.
ChengCLKaoYHLinSJLeeCHLaiML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf2011; 20: 236–42.
32.
SaranRDykstraDMWolfeRAGillespieBHeldPJYoungEW. Association between vascular access failure and the use of specific drugs: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis2002; 40: 1255–63.
33.
JardineMJNinomiyaTPerkovicV. Aspirin is beneficial in hypertensive patients with chronic kidney disease: A post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol2010; 56: 956–65.
34.
DaimonSTeraiH. Influence of antiplatelet medications on bleeding events in hemodialysis patients. Ther Apher Dial2011; 15: 454–9.
35.
OlesenJBLipGYKamperAL. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med2012; 367: 625–35.
36.
CoronelFCigarranSHerreroJA. Morbidity and mortality in diabetic patients on peritoneal dialysis. Twenty-five years of experience at a single centre. Nefrologia2010; 30: 626–32.
37.
CapranzanoPCapodannoD. Dual antiplatelet therapy in patients with diabetes mellitus: Special considerations. Expert Rev Cardiovasc Ther2013; 11: 307–17.
38.
RolliniFFranchiFMuniz-LozanoAAngiolilloDJ. Platelet function profiles in patients with diabetes mellitus. J Cardiovasc Transl Res2013; 6: 329–45.
39.
Tello-MontoliuAFerreiroJLKodaliMK. Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus. J Thromb Thrombolysis2013; 36: 14–7.
40.
GosmanovaEOLeNA. Cardiovascular complications in CKD patients: Role of oxidative stress. Cardiol Res Pract2011; 2011: 156326.
41.
PostorinoMMarinoCTripepiGZoccaliC. Abdominal obesity modifies the risk of hypertriglyceridemia for all-cause and cardiovascular mortality in hemodialysis patients. Kidney Int2011; 79: 765–72.
42.
TuSFChouYCSunCAHsuehSCYangT. The prevalence of metabolic syndrome and factors associated with quality of dialysis among hemodialysis patients in Southern Taiwan. Glob J Health Sci2012; 4: 53–62.
43.
PalmerSCCraigJCNavaneethanSDTonelliMPellegriniFStrippoliGF. Benefits and harms of statin therapy for persons with chronic kidney disease: A systematic review and meta-analysis. Ann Intern Med2012; 157: 263–75.
44.
NavaneethanSDNigwekarSUPerkovicVJohnsonDWCraigJCStrippoliGF. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev2009; (3): CD004289.
